English | 中文版 | 手機版 企業(yè)登錄 | 個人登錄 | 郵件訂閱
當前位置 > 首頁 > 行業(yè)資訊 > 展會 > VIF World 2025第6屆疫苗創(chuàng)新國際論壇通知

VIF World 2025第6屆疫苗創(chuàng)新國際論壇通知

瀏覽次數:525 發(fā)布日期:2024-9-19  來源:本站 本站原創(chuàng),轉載請注明出處
Vaccine Innovation Forum(VIF) World 2025
第6屆疫苗創(chuàng)新國際論壇



 2025年3月20-22日 | 中國 上海

120+演講嘉賓
1000+參會代表
60+展商
30+國家和地區(qū)

持續(xù)推動中國與國際疫苗科學、市場的交流及合作

科學顧問委員會:
Bin Wang,艾棣維欣CSO /復旦大學教授
George Fu Gao, 中科院院士,教授
David Weiner,Wistar研究所執(zhí)行副總裁;美國賓夕法尼亞大學名譽教授
Chunlin Xin,康希諾生物副總裁,
Yuanqing Liu,嘉晨西海中國CSO
Heinrich Haas,英國NeoVac CTO,
Alain Bouckenooghe,Hilleman Laboratories CSO
Shaowei Li,廈門大學教授
Amine Kamen,加拿大麥吉爾大學教授
Kiat Ruxrungtham,泰國朱拉隆功大學Chula疫苗研究中心主任
Dexiang Chen,邁科康生物董事長兼總經理
Anna Du,比爾及梅琳達蓋茨基金會中國國家辦事處高級項目官員
Li Shi,怡道生物董事長
Sean Du,賽諾菲巴斯德全球研發(fā)部亞太地區(qū)外部研發(fā)部負責人
Yuan Yuan,PATH中國國家代表,業(yè)務和聯盟管理負責人
Petro Terblanche,南非Afrigen Biologics CEO
Linqi Zhang,清華大學教授
Xiaofeng Liang,中華預防醫(yī)學會副會長,暨南大學教授
Yuelong Shu, 中國醫(yī)學研究院病原生物學研究所所長
Diana Baraschi,意大利國家研究委員會院士,中國科學院深圳先進技術研究院特聘教授
Emanuele Montomoli, 意大利Siena大學教授/VisMederi創(chuàng)始人&首席科學家
Joon Haeng Rhee,韓國全南國立大學醫(yī)學院教授
Michel De Wilde,前賽諾菲巴斯德研發(fā)部SVP
George Siber,Siber Biotechnologies總裁,約翰霍普金斯大學終身教授
Raman Rao, 新加坡Hilleman Laboratories CEO
Meng Li, 中國生物國際合作部主任
Ruben Rizzi, BioNTech全球法規(guī)事務高級副總裁
Huichen Guo, 蘭州獸醫(yī)研究所研究員
Ken Ishii,日本國際疫苗設計中心主任,東京大學教授

往屆回顧:

 

 
 
主要話題:
創(chuàng)新疫苗開發(fā)進展
新疫苗平臺和技術
基于RNA技術的疫苗及療法
動物疫苗
癌癥疫苗與免疫療法
生物工藝和制造
臨床試驗與疫苗安全性
市場準入、監(jiān)管和國際合作
佐劑、制劑和遞送技術
全球健康與疾病防控

80+早期確認嘉賓:

Rajinder Suri, CEO, DCVMN International, Switzerland
Raches Ella, Chief Development Officer, Bharat Biotech, India
Hun Kim, President of Global Biz, SK bioscience, South Korea
Mahesh Kumar, SVP of R&D, Global Biologics, Zoetis, USA
Simon Graham, Professor, The Pirbright Institute, UK
Jidong Cui, Unit Head, Local Production & Assistance Unit, Innovation and Emerging Technologies Department
(IET),MHP, World Health Organization, Switzerland
Emanuel Montomoli, Professor, Full Prof. of Public Health, University of Siena;CSO of VisMederi Italy
George Siber, President, Siber Biotechnologies LLC, USA
Joon Haeng Rhee, Professor, Chonnam National University Medical School, South Korea
Diana Boraschi, Distinguished Professor, Shenzhen Institute of Advanced Technology, China
Melanie Saville, CSO, PATH, USA
Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
Nikolai Petrovsky, Founder, Vaxine, Australia
Adrian V. S. Hill, Director, The Jenner Institute, Lakshmi Mittal & Family Professor of Vaccinology, University of Oxford , UK
Ruben Rizzi, Senior Vice President Global Regulatory Affairs,BioNTech, Germany
Raman Rao, CEO, the Hilleman Laboratories, Singapore
Meng Li, Director of International Cooperation, China National Biotec Group, China
Bin Wang, Professor, Fudan University/CSO, Advaccine, China
Linqi Zhang, Professor, Tsinghua University, China
Shaowei Li, Professor, Xiamen University, China
Nigel Temperton, Professor, Director, Viral Pseudotype Unit, University of Kent, UK
Kiat Ruxrungtham, Professor of Medicine, Director of Chula VRC, Chulalongkorn University, Thailand
Xiaofeng Liang, VP, Chinese Preventive Medicine Association; Professor, Jinan University, China
Tongqing Zhou, Chief, Structural Bioinformatics Section National Institutes of Health, USA
Shibo Jiang, Professor, Fudan University, China
Wei Tan, SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical, China
Huichen Guo, Professor, Lanzhou Veterinary Research Institute, China
Baik-Lin Seong, Director General, Vaccine Innovative Technogy ALliance (VITAL)-Korea, South Korea
Christopher Netherton, Professor, The Pirbright Institute, UK
Nibal Dahaba, Co-Founder & General manager Emerging markets,Gennecs Holding, Egypt
Jiguo (Jeffrey) Zhang, President, Vaccine Division, Fosun Pharma, China
Petro Terblanche, CEO, Afrigen Biologics, South Africa
Zhaohua (Jessie) Chen, Head of Development China, General Manager of Pfizer China R&D, China
Yuelong Shu, Director, Institute of Pathogen Biology, CAMS & PUMC, China
Robbert van der Most, Former VP, Translational Science Infectious Diseases, BioNTech, CEO, VaxxCellence,Belgium
Jingxin Li, Vice Director of the Department, Jiangsu CDC, China
George Fu Gao, Former Director, China CDC; Academician, Professor, Chinese Academy of Sciences, China
Linfa Wang, Professor, Duke-NUS Medical School, Singapore
Dan Barouch, Professor, Harvard Medical School, USA
Nicaise Ndembi, Head for Partnerships for African Vaccine Manufacturing (PAVM) & Head Science Office, Africa CDC, Ethiopia
Yunlong Richard Cao, Assistant Professor, Peking University, China
Amine Kamen, Professor, McGill University, Canada
Lianpan Dai, Professor, Institute of Microbiology, Chinese Academy of Sciences, China
Han Wang, Associate Professor, Peking University, China
Patrícia Neves, Project Manager, mRNA center,Bio-Manguinhos/ Fiocruz, Brazil
Adel Sattarova, Head of Project activity department, FSUE SPbSRIVS FMBA of Russia
SeyedReza Banihashemi, Director of R&D,Razi Vaccine & Serum Research Institute, Iran
Pardi Norbert, Assistant Professor, Assistant Professor, University of Pennsylvania, USA
Kate Broaderick, Cheif Innovation Officer, Maravai Life Science
Hani Kim, Executive Director, RIGHT Foundation, South Korea
Jian Dong, CEO, WuXi Vaccines; SVP, WuXi Biologics, China
Qihan Li, Professor, Weirui Bio, China
Sean Du, Head, External R&D APAC, Global R&D, Sanofi Pasteur, China
Heinrich Hass, CTO, NeoVac, UK
Kate Broaderick, Chief Innovation Officer, Maravai Life Sciences, USA
Landian Hu, CEO, Anda Biology Medicine Development (Shenzhen)
Adham Rezk, CEO, Celero, Singapore 
Hong Jin, CSO, CyanVac, USA
Nguyen Tuyet Nga, South East Asia Hub Director/Vietnam Country Director, PATH, Vietnam
Peter L. Andersen, Chief Scientific Advisor, Infectious Diseases,Novo Nordisk Foundation, Denmark
Xiangrong Song, Cofounder& CEO, Westgene, China
Jie Li, Head of R&D, The Spirit Jinyu Biological Pharmaceutical, China
SuthiraTaychakhoonavudh,CEO,Baiya Phytopharm, Thailand
Dexiang Chen, CEO, Maxvax, China
Deog-Young Choi, CEO, InThera, South Korea
Yelin Xiong, VP, Yither Biotech, China
Francesca Ceddia, Chief Medical Affairs Officer, Moderna, USA
Zihao Wang, CEO, Immorna Bio, China
Francesco Berlanda Scorza, VP, R&D, Global Health R&D Vaccines Head and GVGH Institute Director, GSK, Italy
Bo Ying, Co-founder, Chairman&CEO, Abogen Biosciences, China
Peter Dull, Deputy Director at Bill & Melinda Gates Foundation, USA
Jiangsheng Xu, Co-founder&CSO, General Therapeutics, USA
Emanuele Andreano, Project Leader, Fondazione Toscana Life Sciences,
Italy
Hao Chen, AVP, Head of Vaccines & Advanced Biotechnologies Process R&D, Merck, USA
Hao Li, Associate Professor, China Agricultural University, China
Xuexiang Han, Professor, SIBCB, China
 
更多嘉賓正在趕來,不容錯過!


 
詳情請至會議官網:

 
聯系主辦方:
Sam Li
13482341046 (微信)
Sam.li@chstone-events.com
ChStone Events
上海崎石商務咨詢有限公司
https://www.bagevent.com/event/8864845


用戶名: 密碼: 匿名 快速注冊 忘記密碼
評論只代表網友觀點,不代表本站觀點。 請輸入驗證碼: 8795
Copyright(C) 1998-2024 生物器材網 電話:021-64166852;13621656896 E-mail:info@bio-equip.com